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National Gay Men’s HIV/AIDS Awareness Day, 
September 27, directs attention to the impact of human 
immunodeficiency virus (HIV) infection and acquired 
immunodeficiency syndrome (AIDS) on gay, bisexual, 
and other men who have sex with men (MSM). In 2017, 
MSM accounted for 67% of new diagnoses of HIV infec-
tion, and MSM who inject drugs an additional 3% (1).
To reduce new infections by 90% in 10 years, the Ending 
the HIV Epidemic national initiative will include efforts to 
increase preexposure prophylaxis (PrEP) use. From 2014 
to 2017, in 20 urban areas, PrEP awareness among MSM 
increased from 60% to 90%, and PrEP use from 6% to 
35% (2). However, a report in this issue of MMWR shows 
that, in 2017, a lower percentage of black and Hispanic 
MSM than white MSM were aware of, had discussed with 
a health care provider, or had used PrEP (3).
CDC supports efforts to reduce HIV infection among 
MSM, including HIV prevention services that increase diag-
nosis of HIV infection (https://www.cdc.gov/hiv/group/
msm/index.html), support the linkage to and engagement of 
MSM in care and treatment, and reduce the risk for acquir-
ing and transmitting HIV (https://www.cdc.gov/hiv/group/
msm/bmsm.html) (https://www.cdc.gov/msmhealth).
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In 2017, preliminary data show that gay, bisexual, and 
other men who have sex with men (MSM) accounted for 
67% of new diagnoses of human immunodeficiency virus 
(HIV) infection, that MSM who inject drugs accounted for an 
additional 3%, and that African American/black (black) and 
Hispanic/Latino (Hispanic) MSM were disproportionately 
affected (1). During 2010–2015, racial/ethnic disparities in 
HIV incidence increased among MSM; in 2015, rates among 
black and Hispanic MSM were 10.5 and 4.9 times as high, 
respectively, as the rate among white MSM (compared with 
9.2 and 3.8 times as high, respectively, in 2010) (2). Increased 
use of preexposure prophylaxis (PrEP), which reduces the risk 
for sexual acquisition of HIV infection by approximately 99% 
when taken daily as prescribed,* would help to reduce these 
disparities and support the Ending the HIV Epidemic: A Plan 
for America initiative† (3). Although PrEP use has increased 
* https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.
† https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/
overview?s_cid=ht_endinghivinternet0002.
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among all MSM since 2014 (4), racial/ethnic disparities in 
PrEP use could increase existing disparities in HIV incidence 
among MSM (5). To understand racial/ethnic disparities in 
PrEP awareness, discussion with a health care provider, and use 
(steps in the HIV PrEP continuum of care) (6), CDC analyzed 
2017 National HIV Behavioral Surveillance (NHBS) data. 
Black and Hispanic MSM were significantly less likely than 
were white MSM to be aware of PrEP, to have discussed PrEP 
with a health care provider, or to have used PrEP within the 
past year. Among those who had discussed PrEP with a health 
care provider within the past year, 68% of white MSM, 62% of 
Hispanic MSM, and 55% of black MSM, reported PrEP use. 
Prevention efforts need to increase PrEP use among all MSM 
and target eliminating racial/ethnic disparities in PrEP use.§
§ https://www.cdc.gov/hiv/risk/prep/index.html.
Data from CDC’s NHBS collected among MSM in 23 U.S. 
urban areas in 2017¶ (7) were analyzed to assess racial/ethnic 
disparities along the HIV PrEP continuum of care. The analysis 
was limited to participants at risk for HIV infection who likely 
met clinical indications for PrEP.** Men with a likely indication 
 ¶ NHBS is cross-sectional biobehavioral surveillance system conducted in U.S. 
urban areas with high HIV prevalence. In 2017, MSM in 23 urban areas 
(Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, 
Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Houston, Texas; 
Los Angeles, California; Memphis, Tennessee; Miami, Florida; Nassau and 
Suffolk counties, New York; New Orleans, Louisiana; New York, New York; 
Newark, New Jersey; Philadelphia, Pennsylvania; Portland, Oregon; San Diego, 
California; San Francisco, California; San Juan, Puerto Rico; Seattle, 
Washington; Virginia Beach, Virginia; and Washington, DC) were recruited 
using venue-based sampling. Eligible participants (men who were born male 
and identified as male, reported having ever had oral or anal sex with another 
man, resided in the interview urban area, and were aged ≥18 years) completed 
standardized questionnaires in English or Spanish administered in person by 
trained interviewers. All participants were offered anonymous HIV testing 
and incentives for the interview and HIV test. The type of incentive (cash or 
gift card) and amount varied by urban area according to formative assessment 
and local policy. A typical incentive included $25 for completing the interview 
and $25 for providing a specimen for HIV testing.
 ** NHBS data do not correspond directly with the criteria for PrEP indication 
in the clinical guidelines. The guidelines recommend that men use PrEP if 
they are without acute or established HIV infection, have had sex with a 
nonmonogamous male partner who has not recently tested HIV-negative, 
and have had at least one of the following: any anal sex without a condom 
within the past 6 months or a bacterial sexually transmitted infection (i.e., 
syphilis, gonorrhea, or chlamydia) diagnosed or reported within the past 
6 months. NHBS data flag persons who are likely indicated for PrEP use 
because of behavior from a longer period (12 months versus 6 months) and 
use multiple sex partners in a year as a proxy for a nonmonogamous partner.
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for PrEP included those who had 1) a negative NHBS HIV 
test result following the NHBS interview††; 2) either multiple 
male sex partners or any male sex partner with HIV infection 
within the past year; and 3) either condomless anal sex or a 
bacterial sexually transmitted infection§§ within the past year. 
Participants were asked whether they were aware of PrEP, 
had discussed PrEP with a health care provider, and had used 
PrEP within the past year.¶¶ Log-linked Poisson regression 
models with generalized estimating equations clustered on 
recruitment event and adjusted for urban area were used to 
estimate adjusted prevalence ratios (aPRs) and 95% confidence 
intervals (CIs). Analyses were conducted using SAS software 
(version 9.4; SAS Institute).
In 2017, a total of 10,104 sexually active MSM were inter-
viewed in 23 U.S. urban areas. This analysis included 4,056 
(40%) MSM (1,843 white MSM, 1,251 Hispanic MSM, and 
962 black MSM) who tested negative for HIV and likely met 
the clinical indications for PrEP. Overall 1,742 (95%) white, 
1,088 (87%) Hispanic, and 825 (86%) black MSM were aware 
of PrEP (white versus Hispanic aPR = 1.1, 95% CI = 1.0–1.1; 
white versus black aPR = 1.1, 95% CI = 1.0–1.1) (Figure). 
However, only 1,063 (58%) white, 546 (44%) Hispanic, 
and 412 (43%) black MSM reported discussing PrEP with a 
health care provider within the past year (white versus Hispanic 
aPR = 1.2, 95% CI = 1.1–1.3; white versus black aPR = 1.2, 
95% CI = 1.1–1.3). Moreover, only 765 (42%) white, 373 
(30%) Hispanic, and 248 (26%) black MSM reported 
taking PrEP within the past year (white versus Hispanic 
aPR = 1.2, 95% CI = 1.1–1.3; white versus black aPR = 1.4, 
95% CI = 1.2–1.6). White MSM were significantly more likely 
than were Hispanic and black MSM to report PrEP awareness, 
discussion with a health care provider, and use.
Among 2,021 MSM who discussed PrEP with their health 
care provider, 225 of 412 (55%) black MSM used PrEP, 
compared with 338 of 546 (62%) Hispanic MSM and 724 
of 1,063 (68%) white MSM (Table). White MSM who dis-
cussed PrEP with their health care provider were significantly 
more likely than were black MSM to use PrEP (aPR = 1.2, 
 †† HIV testing was performed for participants who consented. Blood specimens 
were collected for rapid testing in the field or laboratory-based testing. A 
nonreactive rapid test result was considered negative. A reactive rapid test was 
confirmed with either a second rapid test in the field or supplemental laboratory-
based testing, typically western blot or indirect immunofluorescence assay.
 §§ Syphilis, gonorrhea, or chlamydia.
 ¶¶ Participants were informed that PrEP is an antiretroviral medicine taken for 
months or years by a person who is HIV-negative to reduce the risk of getting 
HIV. Three steps of the HIV PrEP continuum of care were assessed by race/
ethnicity, using the following questions: “Before today, have you ever heard of 
PrEP?” Respondents who answered “Yes” were asked “In the past 12 months, 
have you had a discussion with a health care provider about taking PrEP?” and 
“In the past 12 months, have you taken PrEP to reduce the risk of getting HIV?”
95% CI = 1.1–1.3). This disparity between white and black 
MSM persisted among those who had health insurance 
(aPR = 1.2, 95% CI = 1.1–1.3) and had a usual source of 
health care (aPR = 1.2, 95% CI = 1.1–1.3), which are typi-
cal barriers to accessing prescription medication. Disparities 
in PrEP use between white and black MSM existed in the 
south (aPR = 1.2, 95% CI = 1.1–1.4) and west (aPR = 1.3, 
95% CI = 1.0–1.6) U.S. census regions, whereas disparities 
between white and Hispanic MSM existed only in the south 
(aPR = 1.2, 95% CI = 1.1–1.4).
Discussion
In 2017, the disparities along the HIV PrEP continuum of 
care among black, Hispanic, and white MSM emerged at the 
point of discussion with a health care provider. Among those 
who discussed PrEP with their health care provider, disparities 
in PrEP use existed between black and white MSM. These 
findings highlight the need to address racial/ethnic disparities 
in PrEP awareness, discussions with health care providers, 
and, importantly, use among MSM. Black and Hispanic 
MSM currently experience substantially higher HIV incidence 
than do white MSM (2). Because PrEP effectively prevents 
sexual HIV transmission (3), racial/ethnic disparities in PrEP 
use might further increase disparities in HIV incidence (5). 
Social, structural, and epidemiologic factors are the underlying 
determinants of racial/ethnic health disparities (8). Therefore, 
prevention efforts that address these factors have the potential 
to decrease disparities along the HIV PrEP continuum of care.
Because disparities emerged at the point of discussion with 
a health care provider, interventions that increase PrEP aware-
ness and discussion should include both patients and health 
care providers. As part of its Act Against AIDS campaign (now 
known as Let’s Stop HIV Together***), CDC disseminated 
Start Talking. Stop HIV,††† which encourages MSM to discuss 
PrEP with their health care providers and sexual partners. 
Efforts that increase jurisdiction-level use of this campaign, 
especially in black and Hispanic communities, could help to 
increase awareness, discussion, and use of PrEP.
Although many social and structural factors that exacerbate 
racial/ethnic health disparities also create barriers to accessing 
health care, all persons with access to health care should have 
equal access to treatment. PrEP use among those without 
health insurance was relatively low across racial/ethnic sub-
groups. A recent agreement by Gilead Sciences, Inc. to donate 
 *** https : / /www.cdc.gov/stophivtogether/ index.html?CDC_AA_
refVal=https%3A%2F%2Fwww.cdc.gov%2Factagainstaids%2Fabout 
%2Findex.html.
 ††† https://www.cdc.gov/actagainstaids/campaigns/starttalking/index.html.
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PrEP medication to 200,000 uninsured persons at risk for 
HIV per year, is expected to help close the health care access 
gap.§§§ However, among MSM who discussed PrEP with their 
health care provider, the white versus black disparity in PrEP 
use persisted, even among MSM with health insurance. This 
finding suggests that black MSM face additional barriers to 
PrEP use beyond access to health care. Providers might make 
clinical decisions derived from inaccurate assumptions about 
racial/ethnic minority patients (9). This phenomenon can 
coalesce with patients’ mistrust of health care providers and 
inhibit discussions about PrEP and, ultimately, use of PrEP 
among black and Hispanic MSM. Health care provider train-
ings to promote PrEP discussions might address perceptions 
and assumptions that often limit their likelihood of discussing 
PrEP with MSM patients, especially black MSM (9). Health 
care providers could also benefit from culturally tailored 
trainings on taking a sexual history, which is essential for 
identifying black and Hispanic MSM with PrEP indications. 
Academic detailing and training to increase the number of 
health care providers prescribing PrEP and to enhance quality 
of care for PrEP patients, particularly in black and Hispanic 
 §§§ https://www.hhs.gov/about/news/2019/05/09/trump-administration-secures-
historic-donation-of-billions-of-dollars-in-hiv-prevention-drugs.html.
Summary
What is already known about this topic?
Preexposure prophylaxis (PrEP) reduces the risk for sexual 
human immunodeficiency virus transmission by approximately 
99%. In 2017, approximately one third of gay, bisexual, and 
other men who have sex with men (MSM) reported using PrEP.
What is added by this report?
Although PrEP awareness was high for all racial/ethnic groups, a 
lower percentage of black and Hispanic MSM than white MSM 
had discussed PrEP with a health care provider or had used PrEP 
within the past year.
What are the implications for public health practice?
To expand PrEP use, interventions to increase PrEP awareness, 
encourage health care providers to discuss PrEP, destigmatize PrEP 
use, and promote racial/ethnic equity in PrEP access are needed.
neighborhoods, will also be important in reducing disparities 
(10). Finally, community- and provider-level interventions that 
destigmatize PrEP use, reduce medical mistrust, and educate 
about the prevention benefits of PrEP could be invaluable for 
increasing PrEP use among black and Hispanic MSM (10).
The findings in this report are subject to at least five limita-
tions. First, NHBS uses a 12-month period for assessing risk 
behaviors, whereas the clinical guidelines use a 6-month period. 
FIGURE. Preexposure prophylaxis (PrEP) awareness,* discussion,† and use,§ by race/ethnicity, among men who have sex with men (MSM) with 
a likely indication for PrEP use¶ (N = 4,056) — 23 urban areas, 2017
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Abbreviations: HIV = human immunodeficiency virus; NHBS = National HIV Behavioral Surveillance.
* Respondents with a negative NHBS HIV test result were asked “Preexposure prophylaxis, or PrEP, is an antiretroviral medicine, such as Truvada, taken for months or 
years by a person who is HIV-negative to reduce the risk of getting HIV. Before today, have you ever heard of PrEP?”
† If respondent had heard of PrEP before today, he was asked “In the past 12 months, have you had a discussion with a health care provider about taking PrEP?”
§ If respondent had heard of PrEP before today, he was asked “In the past 12 months, have you taken PrEP to reduce the risk of getting HIV?”
¶ Likely indication for PrEP included men who had 1) a negative NHBS HIV test result; 2) either multiple male sex partners or any male sex partners with HIV infection 
in the past year; and 3) either condomless anal sex or a bacterial sexually transmitted infection in the past year.
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TABLE. Preexposure prophylaxis (PrEP) use among men who have sex with men (MSM) with a likely indication for PrEP use* who have discussed 
PrEP with a health care provider within the past 12 months (N = 2,021), by race/ethnicity and demographic characteristics — 23 urban areas, 2017
Characteristic
Black MSM Hispanic MSM White MSM
White MSM vs. 
black MSM
White MSM vs. 
Hispanic MSM
No. (%) Total No. (%) Total No. (%) Total aPR† (95% CI) aPR† (95% CI)
Overall 225 (54.6) 412 338 (61.9) 546 724 (68.1) 1,063 1.20 (1.08–1.32) 1.06 (0.98–1.14)
Age group (yrs)
18–24 57 (52.3) 109 55 (53.4) 103 71 (55.9) 127 1.03 (0.81–1.32) 1.03 (0.81–1.32)
25–34 116 (57.7) 201 190 (66.0) 288 334 (70.0) 477 1.17 (1.03–1.35) 1.04 (0.94–1.14)
35–44 38 (50.7) 75 67 (62.0) 108 189 (78.4) 241 1.48 (1.16–1.89) 1.21 (1.03–1.42)
≥45 14 (51.9) 27 26 (55.3) 47 130 (59.6) 218 1.09 (0.76–1.58) 0.96 (0.73–1.26)
Education
Less than high school diploma 51 (47.2) 108 47 (57.3) 82 71 (67.0) 106 1.35 (1.06–1.73) 1.11 (0.89–1.40)
Some college or vocational 
school
79 (53.0) 149 127 (61.7) 206 156 (61.2) 255 1.13 (0.94–1.36) 0.98 (0.85–1.14)
College degree or graduate 
studies
94 (61.0) 154 164 (63.6) 258 497 (70.8) 702 1.13 (0.99–1.30) 1.07 (0.96–1.18)
Household income
<$25,000 79 (53.0) 149 72 (57.1) 126 83 (58.9) 141 1.09 (0.87–1.36) 0.98 (0.79–1.20)
$25,000–$49,999 54 (46.2) 117 109 (64.1) 170 155 (66.0) 235 1.39 (1.11–1.73) 1.01 (0.87–1.16)
$50,000–$74,999 42 (62.7) 67 69 (60.5) 114 165 (67.9) 243 1.06 (0.86–1.31) 1.09 (0.92–1.30)
≥$75,000 50 (66.7) 75 87 (64.9) 134 321 (72.3) 444 1.07 (0.91–1.27) 1.07 (0.94–1.23)
Currently have health insurance
No 27 (40.9) 66 37 (50.0) 74 43 (45.3) 95 1.11 (0.76–1.61) 0.89 (0.64–1.23)
Yes 198 (57.2) 346 301 (63.8) 472 681 (70.4) 968 1.19 (1.07–1.32) 1.07 (0.98–1.15)
Usual source of health care when sick or need advice
No 23 (34.8) 66 33 (49.3) 67 30 (44.1) 68 1.22 (0.80–1.87) 0.84 (0.58–1.22)
Yes 202 (58.4) 346 303 (63.8) 475 692 (69.8) 991 1.17 (1.05–1.29) 1.06 (0.98–1.15)
Bacterial STI within the past 12 mos
No 128 (51.8) 247 182 (54.7) 333 430 (63.6) 676 1.18 (1.03–1.34) 1.12 (1.00–1.25)
Yes 97 (58.8) 165 156 (73.2) 213 294 (76.2) 386 1.25 (1.09–1.44) 1.00 (0.91–1.10)
Anal sex without a condom within the past 12 mos
No 10 (41.7) 24 7 (70.0) 10 12 (50.0) 24 1.18 (0.63–2.18) 0.68 (0.36–1.27)
Yes 215 (55.4) 388 330 (61.7) 535 712 (68.5) 1,039 1.18 (1.07–1.31) 1.07 (0.99–1.16)
HIV status of last sex partner
Concordant 124 (51.7) 240 202 (61.0) 331 450 (68.0) 662 1.27 (1.11–1.45) 1.09 (0.99–1.20)
Discordant 32 (76.2) 42 36 (80.0) 45 65 (74.7) 87 0.96 (0.77–1.20) 0.92 (0.74–1.13)
Don’t know HIV status 68 (53.1) 128 99 (59.3) 167 207 (66.6) 311 1.16 (0.96–1.40) 1.04 (0.90–1.20)
Region§
Midwest 21 (55.3) 38 21 (63.6) 33 63 (72.4) 87 1.11 (0.80–1.53) 1.14 (0.86–1.52)
Northeast 64 (55.2) 116 57 (66.3) 86 139 (65.3) 213 1.11 (0.90–1.37) 0.96 (0.80–1.17)
South 99 (54.7) 181 87 (54.0) 161 194 (67.8) 286 1.23 (1.06–1.42) 1.21 (1.02–1.43)
U.S. territories 0 (0.0) 0 4 (19.0) 21 1 (100.0) 1 N/A N/A N/A N/A
West 41 (53.2) 77 169 (69.0) 245 327 (68.7) 476 1.28 (1.03–1.59) 1.00 (0.91– 1.10)
Abbreviations: aPR = adjusted prevalence ratio; CI = confidence interval; HIV = human immunodeficiency virus; N/A = not applicable; STI = sexually transmitted infection.
* Men with a likely indication for PrEP included those who had 1) a negative NHBS HIV test result following the NHBS interview; 2) either multiple male sex partners 
or any male sex partner with HIV infection within the past year; and 3) either condomless anal sex or a bacterial sexually transmitted infection within the past year.
† aPRs were calculated using log-linked Poisson regression models with generalized estimating equations clustered on recruitment event and adjusted for urban area.
§ Midwest region includes Chicago, IL and Detroit, MI. Northeast region includes Boston, MA; Nassau and Suffolk counties, NY; New York City, NY; Newark, NJ; and 
Philadelphia, PA. South region includes Atlanta, GA; Baltimore, MD; Dallas, TX; Houston, TX; Miami, FL; New Orleans, LA; Virginia Beach, VA; and Washington, DC. U.S. 
territories region includes San Juan, PR. West region includes Denver, CO; Los Angeles, CA; Portland, OR; San Diego, CA; San Francisco, CA; and Seattle, WA.
This analysis used having multiple sex partners within the 
past year as a proxy for a nonmonogamous relationship, but 
these partnerships might not have overlapped in time. Thus, 
the analysis might include some men without indications for 
PrEP use. Their inclusion in the denominator might result in 
NHBS underestimation of the percentage of men for whom 
PrEP is indicated who use PrEP. Second, because data were 
not weighted to account for the complex sampling methods 
used to recruit MSM, estimates might be biased by over- or 
underestimating subpopulations. Third, NHBS is not nation-
ally representative and might not be generalizable to all U.S. 
urban areas, nonurban areas, or all MSM. Fourth, data on self-
reported behaviors might be subject to recall and social desir-
ability bias. Social desirability bias might lead to overreporting 
PrEP awareness, discussion, and use. Finally, NHBS does not 
collect data on renal function, and persons with abnormal renal 
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function are considered to have contraindication to PrEP use. 
Thus, it was not possible to adjust for differences in use based 
on medical contraindications.
Protecting persons at risk for HIV through effective, proven 
interventions, such as PrEP, is a pillar of the nation’s Ending 
the HIV Epidemic: A Plan for America initiative (3). PrEP is 
a highly effective and underused prevention tool for all MSM 
at high risk for HIV. Further efforts to improve outcomes 
along the HIV PrEP continuum of care for all MSM and 
to address racial/ethnic disparities, particularly in discussion 
with a health care provider and use, will be critical to reducing 
persistent racial/ethnic disparities in HIV incidence. These 
actions would help achieve the nation’s goal of preventing 
new HIV infections.
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